Association of Lipoprotein(a) With Major Adverse Cardiovascular Events Across Hs-CRP: A Systematic Review and Meta-Analysis

Overview

Journal JACC Adv

Specialty Cardiology & Vascular Diseases

Date 2024 Dec 6

PMID 39640230

Authors

Pamela L Alebna

Chin Yip Han

Mathew Ambrosio

Gwyneth Kong

John W Cyrus

Kayla Harley

Le Kang

Aeron M Small

Parag Chevli

Harpreet Bhatia

Nicholas Chew

Fadi N Salloum

Dave L Dixon

Antonio Abbate

Pradeep Natarajan

Michael D Shapiro

Anurag Mehta

Affiliations

Soon will be listed here.

Abstract

Background: Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease. The relationship between Lp(a) and major adverse cardiovascular events (MACE) in the context of high-sensitivity C-reactive protein (hs-CRP) levels remains controversial due to conflicting results from previous studies.

Objectives: This systematic review and meta-analysis aimed to clarify the association between Lp(a) and risk of MACE across different hs-CRP levels in both primary and secondary prevention settings.

Methods: We performed a systematic review by searching MEDLINE (PubMed), Embase (Ovid), Cochrane CENTRAL (Wiley), and Web of Science (Clarivate) from their inception to February 2024. Eligible studies reported the association of Lp(a) with MACE stratified by hs-CRP level. Data extraction and quality assessment were systematically conducted. Meta-analyses used random-effects models to compute pooled HRs for individuals with low (<2 mg/L) and high (≥2 mg/L) hs-CRP levels. Subgroup analyses were performed in primary and secondary prevention populations.

Results: Nine publications encompassing 11 studies that involved 562,301 participants met the inclusion criteria. The mean proportion of females was 39.9% and the weighted mean age for the entire cohort was 61.2 years. Elevated Lp(a) was significantly associated with MACE risk in both low and high hs-CRP groups, with pooled HR of 1.26 (95% CI: 1.11-1.42) and 1.33 (95% CI: 1.20-1.47), respectively. In the primary prevention group, the pooled HR for low and high hs-CRP groups was 1.33 (95% CI: 1.06-1.66) and 1.43 (95% CI: 1.13-1.82), respectively (subgroup difference, = 0.65). The corresponding HRs for the secondary prevention population were 1.13 (95% CI: 1.00-1.27) and 1.31 (95% CI: 1.12-1.52), respectively (subgroup difference = 0.13).

Conclusion: Elevated Lp(a) is associated with an increased risk of MACE independent of hs-CRP levels in both primary and secondary prevention populations.

References

van der Valk F, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul J . Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation. 2016; 134(8):611-24. PMC: 4995139. DOI: 10.1161/CIRCULATIONAHA.116.020838. View

Reyes-Soffer G, Westerterp M . Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation. Pharmacol Res. 2021; 169:105689. PMC: 9247870. DOI: 10.1016/j.phrs.2021.105689. View

Dzobo K, Kraaijenhof J, Stroes E, Nurmohamed N, Kroon J . Lipoprotein(a): An underestimated inflammatory mastermind. Atherosclerosis. 2022; 349:101-109. DOI: 10.1016/j.atherosclerosis.2022.04.004. View

Tsimikas S . A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017; 69(6):692-711. DOI: 10.1016/j.jacc.2016.11.042. View

Ridker P . A Test in Context: High-Sensitivity C-Reactive Protein. J Am Coll Cardiol. 2016; 67(6):712-723. DOI: 10.1016/j.jacc.2015.11.037. View

Bergmark C, Dewan A, Orsoni A, Merki E, Miller E, Shin M . A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008; 49(10):2230-9. DOI: 10.1194/jlr.M800174-JLR200. View

Yuan D, Wang P, Jia S, Zhang C, Zhu P, Jiang L . Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention. Atherosclerosis. 2022; 363:109-116. DOI: 10.1016/j.atherosclerosis.2022.10.013. View

Nicholls S, Nissen S, Fleming C, Urva S, Suico J, Berg P . Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA. 2023; 330(11):1042-1053. PMC: 10463176. DOI: 10.1001/jama.2023.16503. View

Zhang W, Speiser J, Ye F, Tsai M, Cainzos-Achirica M, Nasir K . High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2021; 78(11):1083-1094. PMC: 8444216. DOI: 10.1016/j.jacc.2021.07.016. View

10.

Reyes-Soffer G, Ginsberg H, Berglund L, Duell P, Heffron S, Kamstrup P . Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2021; 42(1):e48-e60. PMC: 9989949. DOI: 10.1161/ATV.0000000000000147. View

11.

Arnold N, Blaum C, Gossling A, Brunner F, Bay B, Ferrario M . C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project. Eur Heart J. 2024; 45(12):1043-1054. DOI: 10.1093/eurheartj/ehad867. View

12.

Makris A, Barkas F, Sfikakis P, Liberopoulos E, Filippatos T, Ray K . Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?. Atheroscler Plus. 2023; 54:1-6. PMC: 10500445. DOI: 10.1016/j.athplu.2023.09.001. View

13.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

14.

Schnitzler J, Hoogeveen R, Ali L, Prange K, Waissi F, van Weeghel M . Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. Circ Res. 2020; 126(10):1346-1359. PMC: 7208285. DOI: 10.1161/CIRCRESAHA.119.316206. View

15.

Small A, Pournamdari A, Melloni G, Scirica B, Bhatt D, Raz I . Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations. JAMA Cardiol. 2024; 9(4):385-391. PMC: 10867772. DOI: 10.1001/jamacardio.2023.5605. View

16.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

17.

Ridker P, Lei L, Louie M, Haddad T, Nicholls S, Lincoff A . Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance. Circulation. 2023; 149(1):28-35. PMC: 10752259. DOI: 10.1161/CIRCULATIONAHA.123.066213. View

18.

Kronenberg F, Mora S, Stroes E, Ference B, Arsenault B, Berglund L . Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022; 43(39):3925-3946. PMC: 9639807. DOI: 10.1093/eurheartj/ehac361. View

19.

Muller N, Schulte D, Turk K, Freitag-Wolf S, Hampe J, Zeuner R . IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res. 2015; 56(5):1034-42. PMC: 4409280. DOI: 10.1194/jlr.P052209. View

20.

Colantonio L, Bittner V, Safford M, Marcovina S, Brown T, Jackson E . Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease. J Am Heart Assoc. 2022; 11(11):e025397. PMC: 9238745. DOI: 10.1161/JAHA.121.025397. View